Companies holding approved NDAs and ANDAs for GLP1 products should monitor these enforcement trends closely, as they may inform broader brandprotection strategies and provide useful context for evaluating the competitive landscape
No CYP or transporter interactions are flagged
Food and Drug Administration (FDA) recently approved semaglutide (brand name Wegovy) as a chronic weight management treatment for adults with obesity or overweight conditions with at least one weight-related health issue, such as high blood pressure or high cholesterol
Report any unusual side effects or concerns to your healthcare professional promptly
If you purchase a featured product, we may be compensated
Besides, the elevated ratio of free to conjugated BA (CA/GCA + TCA) denoted the enhanced activity of bile salt hydrolase (BSH) (Juarez-Fernandez et al., 2021), which promoted the deconjugation of conjugated BA and conversion to free BA